Skip to main navigation Skip to search Skip to main content

Skin electroporation of a plasmid encoding hCAP-18/LL-37 host defense peptide promotes wound healing

  • Lars Steinstraesser
  • , Martin C. Lam
  • , Frank Jacobsen
  • , Paolo E. Porporato
  • , Kiran Kumar Chereddy
  • , Mustafa Becerikli
  • , Ingo Stricker
  • , Robert EW Hancock
  • , Marcus Lehnhardt
  • , Pierre Sonveaux
  • , Véronique Préat
  • , Gaëlle Vandermeulen

Research output: Contribution to journal › Article › peer-review

Abstract

Host defense peptides, in particular LL-37, are emerging as potential therapeutics for promoting wound healing and inhibiting bacterial growth. However, effective delivery of the LL-37 peptide remains limiting. We hypothesized that skin-targeted electroporation of a plasmid encoding hCAP-18/LL-37 would promote the healing of wounds. The plasmid was efficiently delivered to full-thickness skin wounds by electroporation and it induced expression of LL-37 in the epithelium. It significantly accelerated reepithelialization of nondiabetic and diabetic wounds and caused a significant VEGFa and interleukin (IL)-6 induction. IL-6 was involved in LL-37-mediated keratinocyte migration in vitro and IL-6 neutralizing antibodies delivered to mice were able to suppress the wound healing activity of the hCAP-18/LL-37 plasmid. In a hindlimb ischemia model, electroporation of the hCAP-18/LL-37 plasmid increased blood perfusion, reduced muscular atrophy, and upregulated the angiogenic chemokines VEGFa and SDF-1a, and their receptors VEGF-R and CXCR-4. These findings demonstrate that a localized gene therapy with LL-37 is a promising approach for the treatment of wounds.

Original languageEnglish
Pages (from-to)734-742
Number of pages9
JournalMolecular Therapy
Volume22
Issue number4
DOIs
Publication statusPublished or Issued - Apr 2014
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this